Plain-English translation of NCT05785052 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are searching for biological markers — measurable signs in your blood, urine, and tissue — that could help doctors identify kidney cancer more accurately and understand how serious it might be. This 7-year study will examine samples from people who have been diagnosed with a kidney mass to discover patterns that distinguish cancer from benign masses and predict which cancers are aggressive versus slower-growing.
Right now, doctors don't have reliable, simple tests to diagnose kidney cancer early or predict which patients will have more serious disease. Finding these biological markers could lead to earlier detection and better treatment decisions for people at risk.
If you join, you will donate blood, urine, and possibly tissue samples that doctors will analyze in a laboratory over the 7-year study. The study has two phases: first, researchers will examine stored samples from patients already treated for kidney masses to identify potential markers; second, they will test these markers in new patients to confirm they work. Your participation mainly involves providing biological samples and allowing researchers to access your medical records.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Italy
Spain
Sponsor
Biorek S.R.L.
Enrollment target
~1,000 participants
Started
June 2019
Primary completion
June 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Francesco Trevisani
IRCCS San Raffaele